FERNANDO SERRANO: Open Payments
NPI 1083247779 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,058 in 102 payments from 9 companies in 2025. Trend: 2023 $2,337 · 2024 $3,410 · 2025 $3,058
Food & beverage: $3,048Education: $10
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 21 | $697 |
| Neurocrine BioSciences, Inc. | 11 | $459 |
| E.R. Squibb & Sons, L.L.C. | 11 | $351 |
| Otsuka America Pharmaceutical, Inc. | 13 | $330 |
| Teva Pharmaceuticals USA, Inc. | 13 | $314 |
| Janssen Pharmaceuticals, Inc | 9 | $311 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $249 |
| Vanda Pharmaceuticals Inc. | 9 | $234 |
| Lundbeck LLC | 5 | $113 |
Products named: INGREZZA, ARISTADA, REXULTI, COBENFY, LYBALVI, INVEGA SUSTENNA, CAPLYTA, FANAPT.
Industry payments across CA — which companies pay providers there.
